Immunogenicity Trial of Recombinant Influenza Vaccine Among HCP in Israel

NCT04523324 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

577

Enrollment

FED

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Flublok™ Quadrivalent by Sanofi, Inc.
BIOLOGICAL: VaxigripTetra™ by Sanofi, Inc.

Sponsor

Centers for Disease Control and Prevention

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]